Active, not recruitingPhase 1NCT03893955
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-927(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (26)
- Highlands Oncology Group, PA /ID# 218863, Springdale, Arkansas, United States
- St Jude Hospital dba St Joseph /ID# 211130, Santa Rosa, California, United States
- Yale University School of Medicine /ID# 210678, New Haven, Connecticut, United States
- Moffitt Cancer Center /ID# 215037, Tampa, Florida, United States
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072, Fort Wayne, Indiana, United States
- Washington University-School of Medicine /ID# 221399, St Louis, Missouri, United States
- Duke Cancer Center /ID# 217641, Durham, North Carolina, United States
- Carolina BioOncology Institute /ID# 210664, Huntersville, North Carolina, United States
- UPMC Hillman Cancer Ctr /ID# 222747, Pittsburgh, Pennsylvania, United States
- Tennessee Oncology-Nashville Centennial /ID# 221400, Nashville, Tennessee, United States
- Mary Crowley Cancer Research /ID# 210716, Dallas, Texas, United States
- NEXT Oncology /ID# 210717, San Antonio, Texas, United States
- Virginia Cancer Specialists - Fairfax /ID# 210671, Fairfax, Virginia, United States
- Duplicate_Icon Cancer Centre /ID# 224084, South Brisbane, Queensland, Australia
- Institut de Cancérologie de l'Ouest René Gauducheau /ID# 212880, Saint-Herblain, Loire-Atlantique, France
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03893955 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →